Brought to you by 
Paul Royalty invests $42mm in Guilford, gets royalty rights
14 Jul 2004
Executive Summary
In a deal that will help Guilford Pharmaceuticals fund its acquisition of the cardiovascular drug Aggrastat from Merck & Co., Paul Royalty Funds (PRF)--a unit of Paul Capital Partners set up to acquire royalty and revenue interests of life sciences companies--invested $42mm in the company in exchange for royalties from Guilford's sales of Aggrastat and its brain cancer drug Gliadel.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Paul Royalty invests $42mm in Guilford, gets royalty rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice